EP Wealth Advisors LLC Makes New $201,000 Investment in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

EP Wealth Advisors LLC bought a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 732 shares of the biopharmaceutical company’s stock, valued at approximately $201,000.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Ashton Thomas Private Wealth LLC acquired a new position in Alnylam Pharmaceuticals during the second quarter worth approximately $26,000. Huntington National Bank increased its holdings in shares of Alnylam Pharmaceuticals by 91.8% in the 3rd quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 45 shares during the period. Hollencrest Capital Management purchased a new stake in Alnylam Pharmaceuticals in the 3rd quarter valued at $29,000. Washington Trust Advisors Inc. purchased a new stake in Alnylam Pharmaceuticals in the 3rd quarter valued at $42,000. Finally, True Wealth Design LLC boosted its stake in Alnylam Pharmaceuticals by 15,300.0% during the 3rd quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company’s stock worth $42,000 after purchasing an additional 153 shares during the period. 92.97% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on ALNY shares. Bank of America lifted their price objective on shares of Alnylam Pharmaceuticals from $307.00 to $314.00 and gave the company a “buy” rating in a research note on Monday, October 14th. Wolfe Research downgraded Alnylam Pharmaceuticals from a “peer perform” rating to an “underperform” rating in a research note on Tuesday, November 12th. JPMorgan Chase & Co. increased their price objective on Alnylam Pharmaceuticals from $248.00 to $280.00 and gave the stock a “neutral” rating in a research report on Monday, August 26th. StockNews.com lowered Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, November 28th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $400.00 price target on shares of Alnylam Pharmaceuticals in a report on Monday, November 18th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and eighteen have issued a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $298.09.

Insider Buying and Selling at Alnylam Pharmaceuticals

In related news, CMO Pushkal Garg sold 1,752 shares of the firm’s stock in a transaction that occurred on Thursday, December 12th. The shares were sold at an average price of $251.00, for a total transaction of $439,752.00. Following the sale, the chief marketing officer now owns 15,705 shares in the company, valued at approximately $3,941,955. This trade represents a 10.04 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Yvonne Greenstreet sold 5,219 shares of the business’s stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total value of $1,309,864.62. Following the completion of the transaction, the chief executive officer now owns 78,880 shares of the company’s stock, valued at $19,797,302.40. This trade represents a 6.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 10,122 shares of company stock worth $2,540,455. 1.50% of the stock is owned by insiders.

Alnylam Pharmaceuticals Trading Up 0.1 %

NASDAQ:ALNY opened at $245.44 on Friday. Alnylam Pharmaceuticals, Inc. has a 52-week low of $141.98 and a 52-week high of $304.39. The company has a quick ratio of 2.69, a current ratio of 2.75 and a debt-to-equity ratio of 31.64. The stock has a fifty day simple moving average of $267.01 and a 200-day simple moving average of $248.85. The company has a market capitalization of $31.66 billion, a PE ratio of -93.68 and a beta of 0.32.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.36). The business had revenue of $500.90 million for the quarter, compared to the consensus estimate of $532.91 million. During the same period in the prior year, the firm posted $1.15 EPS. The company’s revenue was down 33.3% compared to the same quarter last year. On average, equities research analysts expect that Alnylam Pharmaceuticals, Inc. will post -2.21 earnings per share for the current fiscal year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.